SCHEMBL4917809

SCHEMBL4917809

CC(=O)c1cccc(CNc2nc(Nc3cccc(NS(C)(=O)=O)c3)nc3[nH]cnc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTK2 Q05397 6/20 0.43
CYP1A2 P05177 9/20 0.41
CYP3A4 P08684 9/20 0.41
CYP2D6 P10635 8/20 0.41
CYP2C19 P33261 8/20 0.41
TSHR P16473 5/20 0.41
USP2 O75604 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
CLK4 Q9HAZ1 1/20 0.41
PDE5A O76074 2/20 0.40
CYP2C9 P11712 6/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4918965 0.91 PTK2 (0.50) PTK2CYP3A4CLK4PDE5AMAPK1
SCHEMBL4919702 0.89 PDE5A (0.42) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6
SCHEMBL4916374 0.88 PDE5A (0.50) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6
SCHEMBL4909992 0.87 PDE5A (0.43) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6
SCHEMBL4912787 0.87 PTK2 (0.51) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6
SCHEMBL4920046 0.87 PTK2 (0.48) PTK2PDE5A
SCHEMBL4914819 0.86 PDE5A (0.44) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6
SCHEMBL4917738 0.85 MAPT (0.46) ALDH1A1PTK2TSHRMEN1KMT2A
SCHEMBL4917319 0.85 PTK2 (0.45) PTK2PDE5A
SCHEMBL4920844 0.85 CYP1A2 (0.55) ALDH1A1PTK2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK ALDH1A1 2994/4885SMN1; SMN2 3036/4885PTK2 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.